Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas

Anti-Cancer Drugs

Volumn 26, Issue 3, 2015, Pages 293-300

  He, Weiliang ^a,b,c,d   Liu, Ran ^e   Yang, Shao Hua ^a,b,c,e   Yuan, Fang ^a,b,c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d HEBEI MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

glioma; mitochondria; tamoxifen; temozolomide

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TEMOZOLOMIDE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL VIABILITY ASSAY; DNA ISOLATION; DRUG CYTOTOXICITY; DRUG EFFECT; GLIOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; MALE; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; RAT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; METHYLATION; MITOCHONDRION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ELECTRON TRANSPORT COMPLEX I; GLIOMA; HUMANS; MALE; METHYLATION; MITOCHONDRIA; PROMOTER REGIONS, GENETIC; RATS, SPRAGUE-DAWLEY; TAMOXIFEN; TUMOR SUPPRESSOR PROTEINS;

EID: 84925538003     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000197     Document Type: Article

References (27)

1. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000; 6:2585-2597.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459-466.
3. Jhaveri N, Cho H, Torres S, Wang W, Schönthal AH, Petasis NA, et al. Noscapine inhibits tumor growth in TMZ-resistant gliomas. Cancer Lett 2011; 312:245-252.
4. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990; 50:6119-6129.
5. Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 1995; 51:167-223.
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.
7. Jan CR, Cheng JS, Chou KJ,Wang SP, Lee KC, Tang KY, et al. Dual effect of tamoxifen, an anti-breast-cancer drug, on intracellular Ca(2 +) and cytotoxicity in intact cells. Toxicol Appl Pharmacol 2000; 168:58-63.
8. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, Weiss MH, Law RE. Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 1994; 345:43-46.
9. Puchner MJ, Köppen JA, Zapf S, Knabbe C, Westphal M. The influence of tamoxifen on the secretion of transforming growth factor-beta2 (TGF-beta2) in glioblastomas: in vitro and in vivo findings. Anticancer Res 2002; 22 (1A):45-51.
10. Moodbidri MS, Shirsat NV. Activated JNK brings about accelerated apoptosis of Bcl-2-overexpressing C6 glioma cells on treatment with tamoxifen. J Neurochem 2005; 92:1-9.
11. Tseng SH, Wang CH, Lin SM, Chen CK, Huang HY, Chen Y. Activation of c-Jun N-terminal kinase 1 and caspase 3 in the tamoxifen-induced apoptosis of rat glioma cells. J Cancer Res Clin Oncol 2004; 130:285-293.
12. Couldwell WT, Antel JP, Yong VW. Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery 1992; 31:717-724, discussion 724.
13. Misir Krpan A, Ivankovic S, Krajina Z, Ivankovic D, Stojkovic R. Tamoxifen in trimodal therapy with cytotoxic drugs and hyperthermia in vivo significantly enhance therapeutic efficacy against B16-F10 melanoma. Tumori 2012; 98:257-263.
14. Lee S, Kim WH, Jung HY, Yang MH, Kang GH. Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol 2002; 161:1015-1022.
15. Sathornsumetee S, Rich JN. New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther 2006; 6:1087-1104.
16. Wei Z, Tao J, Fang Y, Guilin L, Liping D, Lixin X, et al. In vitro chemosensitivity test of glioma cells in tissue culture. Chinese J Minimally Invasive Neurosurg 2007; 12:163-166.
17. Grilli S. Tamoxifen (TAM): the dispute goes on. Ann Ist Super Sanita 2006; 42:170-173.
18. Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo ML, et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996; 2:619-622.
19. Ueda S, Mineta T, Nakahara Y, Okamoto H, Shiraishi T, Tabuchi K. Induction of the DNA repair gene O6-methylguanine-DNA methyltransferase by dexamethasone in glioblastomas. J Neurosurg 2004; 101:659-663.
20. Blough MD, Zlatescu MC, Cairncross JG. O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells. Cancer Res 2007; 67:580-584.
21. Gradishar WJ. Adjuvant endocrine therapy for early breast cancer: the story so far. Cancer Invest 2010; 28:433-442.
22. Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res 2009; 15:7092-7098.
23. Couldwell WT, Uhm JH, Antel JP, Yong VW. Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery 1991; 29:880-886, discussion 886-7.
24. Cardoso CM, Custódio JB, Almeida LM, Moreno AJ. Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. Toxicol Appl Pharmacol 2001; 176:145-152.
25. Lobatón CD, Vay L, Hernández-Sanmiguel E, Santodomingo J, Moreno A, Montero M, Alvarez J. Modulation of mitochondrial Ca(2+) uptake by estrogen receptor agonists and antagonists. Br J Pharmacol 2005; 145:862-871.
26. Robins HI, Won M, Seiferheld WF, Schultz CJ, Choucair AK, Brachman DG, et al. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro Oncol 2006; 8:47-52.
27. DI Cristofori A, Carrabba G, Lanfranchi G, Menghetti C, Rampini P, Caroli M. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. Anticancer Res 2013; 33:3383-3389.